Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far?
Publication
, Journal Article
Powers, WJ
Published in: JAMA
July 10, 2018
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
July 10, 2018
Volume
320
Issue
2
Start / End Page
141 / 143
Location
United States
Related Subject Headings
- Treatment Outcome
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Stroke
- Humans
- General & Internal Medicine
- Fibrinolytic Agents
- Brain Ischemia
- 42 Health sciences
- 32 Biomedical and clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Powers, W. J. (2018). Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far? JAMA, 320(2), 141–143. https://doi.org/10.1001/jama.2018.8511
Powers, William J. “Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far?” JAMA 320, no. 2 (July 10, 2018): 141–43. https://doi.org/10.1001/jama.2018.8511.
Powers WJ. Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far? JAMA. 2018 Jul 10;320(2):141–3.
Powers, William J. “Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far?” JAMA, vol. 320, no. 2, July 2018, pp. 141–43. Pubmed, doi:10.1001/jama.2018.8511.
Powers WJ. Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far? JAMA. 2018 Jul 10;320(2):141–143.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
July 10, 2018
Volume
320
Issue
2
Start / End Page
141 / 143
Location
United States
Related Subject Headings
- Treatment Outcome
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Stroke
- Humans
- General & Internal Medicine
- Fibrinolytic Agents
- Brain Ischemia
- 42 Health sciences
- 32 Biomedical and clinical sciences